Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies
出版年份 2021 全文链接
标题
Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies
作者
关键词
-
出版物
Blood Cancer Journal
Volume 11, Issue 7, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-07-09
DOI
10.1038/s41408-021-00518-z
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial
- (2021) Peter Borchmann et al. LANCET ONCOLOGY
- Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma
- (2021) Reid W. Merryman et al. LEUKEMIA
- Dose-Intensification in Early Unfavorable Hodgkin Lymphoma: Long-Term Follow up of the German Hodgkin Study Group (GHSG) HD14 Trial
- (2020) Sarah Gillessen et al. BLOOD
- Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort
- (2020) Reid W Merryman et al. BLOOD
- PET-Adapted Nivolumab or Nivolumab Plus ICE As First Salvage Therapy in Relapsed or Refractory Hodgkin Lymphoma
- (2020) Alex F. Herrera et al. BLOOD
- Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study
- (2020) Alison J. Moskowitz et al. BLOOD
- Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥60 Years
- (2020) Christopher A. Yasenchak et al. BLOOD
- Brentuximab Vedotin in First Refractory/Relapsed Classical Hodgkin Lymphoma Patients Treated By Chemotherapy (ICE) before Autologous Transplantation. Final Analysis of Phase II Study
- (2020) Aspasia Stamatoullas et al. BLOOD
- Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study
- (2020) David J. Straus et al. BLOOD
- Safety and efficacy of four cycles of Brentuximab Vedotin as consolidation after autologous peripheral stem cell transplantation in relapsed/refractory Hodgkin lymphoma
- (2020) Jeries Kort et al. LEUKEMIA & LYMPHOMA
- Clinical activity of ibrutinib in classical Hodgkin lymphoma relapsing after allogeneic stem cell transplantation is independent of tumor BTK expression
- (2020) Talha Badar et al. BRITISH JOURNAL OF HAEMATOLOGY
- KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).
- (2020) John Kuruvilla et al. JOURNAL OF CLINICAL ONCOLOGY
- Posttransplant cyclophosphamide after allogeneic hematopoietic cell transplantation mitigates the immune activation induced by previous nivolumab therapy
- (2020) Juan C. Nieto et al. LEUKEMIA
- Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma
- (2020) Paul J. Bröckelmann et al. JAMA Oncology
- A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma
- (2020) Nancy L. Bartlett et al. BLOOD
- Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma
- (2020) Carlos A. Ramos et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab followed by AVD in untreated early unfavorable and advanced stage classical Hodgkin lymphoma
- (2020) Pamela Blair Allen et al. BLOOD
- Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial
- (2020) Catherine S Diefenbach et al. Lancet Haematology
- PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation
- (2019) Philippe Armand et al. BLOOD
- Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation
- (2019) Guillaume Manson et al. EUROPEAN JOURNAL OF CANCER
- ANALYSIS OF CLINICAL DETERMINANTS DRIVING SAFETY AND EFFICACY OF CAMIDANLUMAB TESIRINE (ADCT-301, CAMI) IN RELAPSED/REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL)
- (2019) G. Collins et al. HEMATOLOGICAL ONCOLOGY
- Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma – a LWP‐EBMT study
- (2019) Ali Bazarbachi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Prednisone, Vinblastine, Doxorubicin and Bendamustine (PVAB) Regimen in First Line Therapy for Older Patients with Advanced-Stage Classical Hodgkin Lymphoma: Results of a Prospective Multicenter Phase II Trial of the Lymphoma Study Association (LYSA)
- (2019) Herve Ghesquieres et al. BLOOD
- Safety Analysis of Brentuximab Vedotin from the Phase III AETHERA Trial in Hodgkin Lymphoma in the Post-Transplant Consolidation Setting
- (2018) Auayporn Nademanee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial
- (2018) Anne-Ségolène Cottereau et al. BLOOD
- Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma
- (2018) Ann S. LaCasce et al. BLOOD
- Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin’s lymphoma undergoing allogeneic haematopoietic cell transplantation—a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy
- (2018) Jordan Gauthier et al. BONE MARROW TRANSPLANTATION
- Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party
- (2018) Ali Bazarbachi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
- (2018) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors Before and After Allogeneic transplantation
- (2018) Awais Ijaz et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse
- (2018) Craig H. Moskowitz et al. BLOOD
- Randomized phase III study comparing an early PET driven treatment de-escalation to a not PET-monitored strategy in patients with advanced stages Hodgkin lymphoma: Final analysis of the AHL2011 LYSA study.
- (2018) Olivier Casasnovas et al. JOURNAL OF CLINICAL ONCOLOGY
- Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party
- (2018) Ali Bazarbachi et al. CANCER
- Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials
- (2017) Stephanie Sasse et al. JOURNAL OF CLINICAL ONCOLOGY
- PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group
- (2017) Peter Borchmann et al. LANCET
- FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma
- (2017) Yvette L. Kasamon et al. ONCOLOGIST
- Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma
- (2016) Scott D. Ramsey et al. BRITISH JOURNAL OF HAEMATOLOGY
- Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30 + Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program
- (2016) Aurore Perrot et al. HAEMATOLOGICA
- Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma
- (2016) Peter Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30 + Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program
- (2016) Aurore Perrot et al. HAEMATOLOGICA
- Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma
- (2015) John Radford et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bendamustine Combined with Donor Lymphocytes Infusion in Hodgkin's Lymphoma Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation
- (2014) Elisa Sala et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma
- (2014) Salim Kanoun et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitions
- (2013) B. Klimm et al. ANNALS OF ONCOLOGY
- Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study
- (2013) Anas Younes et al. LANCET ONCOLOGY
- Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients
- (2013) Hervé Ghesquières et al. LEUKEMIA & LYMPHOMA
- Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma
- (2012) Gaetano Corazzelli et al. BRITISH JOURNAL OF HAEMATOLOGY
- Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial
- (2012) Bastian von Tresckow et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Bendamustine in Relapsed and Refractory Hodgkin Lymphoma
- (2012) Alison J. Moskowitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Early-Stage Hodgkin's Lymphoma
- (2010) James O. Armitage NEW ENGLAND JOURNAL OF MEDICINE
- Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC–GELA H8 randomised controlled trial
- (2009) Natacha Heutte et al. LANCET ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search